Loading clinical trials...
Loading clinical trials...
A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors
Conditions
Interventions
R-5780
Locations
1
United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Start Date
August 1, 2025
Primary Completion Date
April 30, 2027
Completion Date
December 31, 2027
Last Updated
September 4, 2025
NCT06132828
NCT06144671
NCT04570423
NCT07489378
NCT06926283
NCT07177937
Lead Sponsor
Rise Therapeutics LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions